Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15160952rdf:typepubmed:Citationlld:pubmed
pubmed-article:15160952lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0038250lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0025241lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0146224lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C1823138lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C1317973lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0183683lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0344211lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C1521721lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:15160952lifeskim:mentionsumls-concept:C1171411lld:lifeskim
pubmed-article:15160952pubmed:issue4lld:pubmed
pubmed-article:15160952pubmed:dateCreated2004-5-26lld:pubmed
pubmed-article:15160952pubmed:abstractTextThe goal of this trial was to assess the toxicity and potential efficacy of high-dose topotecan, melphalan and cyclophosphamide as a preparative regimen for patients with multiple myeloma undergoing autologous stem cell transplantation. Eighteen patients were treated, 8 for first remission consolidation, 4 with relapse sensitive disease, 3 primary refractory and 3 relapsed refractory. The median age was 56 (38 - 65) and the median number of prior regimens was 3 (1 - 8). Patients received cyclophosphamide 1 g/m2/d on days -6, -5, -4; melphalan 70 mg/m2 on days -3, -2 and topotecan 3.0 to 3.5 mg/m2/d on days -6 to -2. Peripheral blood stem cells were infused on day 0. Toxicity (Bearman Toxicity Criteria) was mostly limited to grade 1 - 2 mucositis and grade 1 diarrhea. There were no transplant-related deaths. The overall response rate at 3 months post transplantation was 89% with 17% CR, 2 of those in refractory patients. The overall response rate in refractory patients was 67%. With a median follow up of 12.3 months, 89% of patients are alive. The TMC regimen is well tolerated and produces high response rates. Further evaluation of TMC to fully assess response and survival is ongoing.lld:pubmed
pubmed-article:15160952pubmed:languageenglld:pubmed
pubmed-article:15160952pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15160952pubmed:citationSubsetIMlld:pubmed
pubmed-article:15160952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15160952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15160952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15160952pubmed:statusMEDLINElld:pubmed
pubmed-article:15160952pubmed:monthAprlld:pubmed
pubmed-article:15160952pubmed:issn1042-8194lld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:GiraltSergioSlld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:Anagnostopoul...lld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:WeberDonnaDlld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:ChamplinRicha...lld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:AlexanianRaym...lld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:DonatoMichele...lld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:AlemanAnaAlld:pubmed
pubmed-article:15160952pubmed:authorpubmed-author:IppolitiCindy...lld:pubmed
pubmed-article:15160952pubmed:issnTypePrintlld:pubmed
pubmed-article:15160952pubmed:volume45lld:pubmed
pubmed-article:15160952pubmed:ownerNLMlld:pubmed
pubmed-article:15160952pubmed:authorsCompleteYlld:pubmed
pubmed-article:15160952pubmed:pagination755-9lld:pubmed
pubmed-article:15160952pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:meshHeadingpubmed-meshheading:15160952...lld:pubmed
pubmed-article:15160952pubmed:year2004lld:pubmed
pubmed-article:15160952pubmed:articleTitleHigh-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.lld:pubmed
pubmed-article:15160952pubmed:affiliationDepartment of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA. mdonato@mdanderson.orglld:pubmed
pubmed-article:15160952pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15160952pubmed:publicationTypeClinical Triallld:pubmed